XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
B
B

Biomarin

市场新闻

Reuters - 1天前

Ascendis Pharma slips after $300 mln share offering launch

BUZZ-Ascendis Pharma slips after $300 mln share offering launch ** U.S.-listed shares of Ascendis Pharma ASND.O down 4.3% at $142.50 in extended trading as co seeks equity raise ** Denmark-based biopharma announces $300 mln offering of American depositary shares (ADSs) ** JP Morgan, Morgan Stanley, Evercore and Goldman Sachs are jt bookrunners ** On Mon, ASND shares closed up ~17% at $139.57 after co said its achondroplasia therapy TransCon CNP met main goal in trial to treat dwarfism ** Shares
B
G
J
Reuters - 3天前

U.S. Aerovironment, Insulet, Viasat

U.S. RESEARCH ROUNDUP- Aerovironment, Insulet, Viasat Sept 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aerovironment, Insulet and Viasat, on Tuesday. HIGHLIGHTS * Aerovironment Inc AVAV.O : Raymond James cuts to market perform from outperform * Frontier Communications Parent Inc FYBR.O : JP Morgan cuts to neutral from overweight * Insulet Corp PODD.O : Piper Sandler raises target price to $285 from $230 * Relm
B
C
C
E
I
D
Reuters - 3天前

Ascendis rises on positive trial data for dwarfism therapy

BUZZ-Ascendis rises on positive trial data for dwarfism therapy ** U.S.-listed shares of Denmark-based Ascendis Pharma A71.F , ASND.O rise 17.3% to $139.88 ** ASND says its achondroplasia therapy TransCon CNP met its main goal by showing an average growth velocity of 5.89 cm/year vs 4.41 cm/year for a placebo in a trial ** Achondroplasia is a form
B
Reuters - 2周前

U.S. Coca-Cola, KB Home, Newmark Group

U.S. RESEARCH ROUNDUP-Coca-Cola, KB Home, Newmark Group Sept 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola, KB Home and Newmark Group on Thursday. HIGHLIGHTS * Capital Clean Energy Carriers CCEC.O : Evercore ISI initiates coverage with outperform rating * Coca-Cola Co KO.N : CFRA cuts to hold from buy * KB Home KBH.N : RBC cuts to underperform from sector perform * Newmark Group Inc NMRK.O : KBW raises
B
U
C
D
C
C
L
Reuters - 2周前

Biomarin Pharmaceutical Says On Aug 28, Entered Into Credit Agreement For Up To $600 Million In Revolving Loans

BRIEF-Biomarin Pharmaceutical Says On Aug 28, Entered Into Credit Agreement For Up To $600 Million In Revolving Loans Sept 4 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : BIOMARIN PHARMACEUTICAL: ON AUG 28, ENTERED INTO CREDIT AGREEMENT FOR UP TO $600 MILLION IN REVOLVING LOANS BIOMARIN PHARMACEUTICAL: CO WILL BE ENTITLED TO DRAW FUNDS AT ITS DI
B
Reuters - 2周前

Biomarin Holds Investor Day; Provides New Corporate Strategy And Introduces 2027 Financial Guidance

BRIEF-Biomarin Holds Investor Day; Provides New Corporate Strategy And Introduces 2027 Financial Guidance Sept 4 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : BIOMARIN HOLDS INVESTOR DAY; PROVIDES NEW CORPORATE STRATEGY AND INTRODUCES 2027 FINANCIAL GUIDANCE BIOMARIN PHARMACEUTICAL: SEES FY 2027 TOTAL REVENUES $4 BILLION BIOMARIN PHARMACEUTICAL:
B
Reuters - 3周前

BioMarin to reduce global workforce by about 225 employees

UPDATE 2-BioMarin to reduce global workforce by about 225 employees Adds job reduction details in paragraphs 4-6 Aug 28 (Reuters) - BioMarin Pharmaceutical BMRN.O w ill reduce its global workforce by about 225 employees, a filing showed on Wednesday. The decision comes in the wake of the company's updated strategy for its hemophilia gene therapy, Roctavian, and the discontinuation of its gene therapy BMN 293 development program.
B
Reuters - 3周前

BioMarin to reduce global workforce by about 225 employees

BioMarin to reduce global workforce by about 225 employees Aug 28 (Reuters) - BioMarin Pharmaceutical BMRN.O has decided to reduce its global workforce by about 225 employees, a filing showed on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel
B
Reuters - 4周前

U.S. Agree Realty, Global Payments, Snowflake

U.S. RESEARCH ROUNDUP- Agree Realty, Global Payments, Snowflake Aug 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agree Realty, Global Payments and Snowflake on Wednesday. HIGHLIGHTS * Agree Realty Corp ADC.N : Raymond James raises target price to $81 from $70 * Coinbase Global Inc COIN.O : Jefferies cuts target price to $220 from $245 * Global Payments Inc GPN.N : Jefferies raises target price to $130 from $120
A
B
C
C
P
V
E
G
M
K
L
Reuters - 4周前

U.S. Alight, Mastercard, Visa

U.S. RESEARCH ROUNDUP-Alight, Mastercard, Visa Aug 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alight, Mastercard and Visa, on Tuesday. HIGHLIGHTS * Alight Inc ALIT.N : JP Morgan cuts to neutral from overweight * Biomarin Pharmaceutical Inc BMRN.O : Bernstein raises to outperform from market-perform * Liquidia Corp LQDA.O : Raymond James raises to strong buy from outperform * Mastercard MA.N : JP Morgan raises
A
A
B
D
P
P
V
A
D
T
A
E
F
G
Z
B
D
Reuters - 1个月前

U.S. STOCKS IDEXX, Amgen, Airbnb

BUZZ-U.S. STOCKS ON THE MOVE-IDEXX, Amgen, Airbnb Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose over 1% on Tuesday, as investors looked for bargains after a global stock selloff and dovish comments from Federal Reserve officials lifted market sentiment.
A
A
B
I
U
U
F
M
R
U
V
M
Reuters - 2个月前

U.S. STOCKS Lumen Technologies, Broadridge Financial, IDEXX

BUZZ-U.S. STOCKS ON THE MOVE-Lumen Technologies, Broadridge Financial, IDEXX Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose over 1% on Tuesday, as investors looked for bargains after a global stock selloff and dovish comments from Federal Reserve officials lifted market sentiment.
A
A
B
C
I
U
U
F
M
R
T
U
B
J
M
Reuters - 2个月前

BioMarin up as investors applaud new focus for hemophilia gene therapy

BUZZ-BioMarin up as investors applaud new focus for hemophilia gene therapy ** Shares of BioMarin Pharmaceutical BMRN.O rise ~8% to hit over 3-month high of $86.48 ** BMRN plans to cut direct annual expenses for its hemophilia gene therapy, Roctavian , by directing commercial focus to markets in the U.S., Germany and Italy ** Co anticipates reducing annual direct expenses on Roctavian to ~$60 million beginning in 2025 ** "Investors appear to be applauding the decision to downsize Roctavian's exp
B
Reuters - 2个月前

Leerink views Lilly and Sarepta as defensive stocks in turbulent market

BUZZ-Leerink views Lilly and Sarepta as defensive stocks in turbulent market ** Brokerages Leerink Partners says Eli Lilly LLY.N and Sarepta Therapeutics SRPT.O are among stocks it expects to outperform the broader market in "this turbulent period" of recession concerns ** Brokerage expects strong performance from the weight-loss and diabetes drug maker LLY on Wed, when it reports its earnings ** SRPT is a "a potential haven for investors seeking downside protection in a choppy market" due to po
A
B
M
T
Reuters - 2个月前

U.S. Actinium, Albemarle, ArcBest

U.S. RESEARCH ROUNDUP- Actinium, Albemarle, ArcBest Aug 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Actinium Pharmaceuticals, Albemarle and ArcBest, on Tuesday. HIGHLIGHTS * Actinium Pharmaceuticals Inc ATNM.A : JonesTrading cuts PT to $9 from $26 * Albemarle ALB.N : Baird cuts to neutral; cuts target price to $85 from $102 * ArcBest Corp ARCB.O : Stephens cuts target price to $130 from $145 * Crispr Therapeuti
A
A
B
B
C
C
C
C
D
Reuters - 2个月前

Biomarin Pharmaceutical Inc reports results for the quarter ended in June - Earnings Summary

Biomarin Pharmaceutical Inc reports results for the quarter ended in June - Earnings Summary Biomarin Pharmaceutical Inc BMRN.OQ reported quarterly adjusted earnings of 56 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 29 cents. The mean expectation of twenty five analysts for the quarter was for earnings of 35 cents per share.
B
Reuters - 2个月前

BioMarin climbs after Q2 results beat

BUZZ-BioMarin climbs after Q2 results beat ** Shares of therapy developer BioMarin BMRN.O rise ~5.6% to $84.99 in after-hours trading ** BMRN reports Q2 adj. profit of 96 cents/shr vs analysts' average estimate of 35 cents/shr - LSEG data ** Company's quarterly revenue of $712 mln also beats analysts' expectation of $662.1 mln ** BMRN forecasts annual adj.
B
Reuters - 2个月前

Biomarin Pharmaceutical Q2 EPS USD 0.55

BRIEF-Biomarin Pharmaceutical Q2 EPS USD 0.55 Aug 05 (Reuters) - Biomarin Pharmaceutical Q2 revenue USD 712 million vs. IBES estimate USD 662.1 million. Q2 basic EPS USD 0.56 Q2 adjusted EPS USD 0.96 vs. IBES estimate USD 0.35 Q2 net income USD 107.2 million vs. IBES estimate USD 70.5 million
B
Reuters - 2个月前

US FDA Approves Biomarin's Brineura For Children Under 3 Years With CLN2 Disease

BRIEF-US FDA Approves Biomarin's Brineura For Children Under 3 Years With CLN2 Disease July 24 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : U.S. FOOD AND DRUG ADMINISTRATION APPROVES BIOMARIN'S BRINEURA® (CERLIPONASE ALFA) FOR CHILDREN UNDER 3 YEARS WITH CLN2 DISEASE Source text for Eikon: ID:nPn4g5vV5a Further company coverage: BMRN.O
B
Reuters - 2个月前

Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial

UPDATE 1-Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial Adds background on data and disorder throughout July 24 (Reuters) - Pfizer's PFE.N gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment, the company said on Wednesday.
B
P

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。